4-{[5-(1-Methyl-1,7-diazaspiro[4.4]nonan-7-yl)pyridin-3-yl]oxy}phenol | 646056-32-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-{[5-(1-Methyl-1,7-diazaspiro[4.4]nonan-7-yl)pyridin-3-yl]oxy}phenol
• 英文别名: 4-[5-(1-methyl-1,7-diazaspiro[4.4]nonan-7-yl)pyridin-3-yl]oxyphenol
• CAS: 646056-32-8
• 化学式: C₁₉H₂₃N₃O₂
• 分子量: 325.4
• InChiKey: LELIOHKUILMOBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  48.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
  申请人：Targacept, Inc.

  公开号：US20040067930A1

  公开（公告）日：2004-04-08

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本文公开了N-芳基二氮杂螺环化合物、N-杂芳基二氮杂螺环化合物的桥接类似物、以及这些化合物的前药或代谢物的制备和使用方法。芳基可以是五元或六元杂环（杂芳基）。这些化合物和组合物可用于治疗和/或预防各种疾病或障碍，特别是那些以尼古丁胆碱能神经递质功能障碍为特征的障碍，包括涉及神经递质释放的神经调节障碍，例如多巴胺释放。中枢神经系统障碍是另一个可以治疗和/或预防的例子，其特征是正常神经递质释放的改变。这些化合物和组合物也可用于缓解疼痛。这些化合物可以：（i）改变患者的大脑中尼古丁胆碱能受体的数量，（ii）表现出神经保护作用，以及（iii）在有效剂量下，不会导致明显的不良副作用（例如，明显增加血压和心率、对胃肠道的明显负面影响以及对骨骼肌的明显影响等副作用）。
• Use of N-aryl diazaspiracyclic compounds in the treatment of addiction
  申请人：Bhatti S. Balwinder

  公开号：US20060058328A1

  公开（公告）日：2006-03-16

  Compounds, compositions and methods for treating drug addiction, nicotine addiction, and/or obesity are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds are effective at inhibiting dopamine production and/or secretion, and accordingly are effective at inhibiting the physiological “reward” process that is associated with ingestion of nicotine and/or illicit drugs. The compounds and compositions can be administered in effective amounts to inhibit dopamine release, without resulting in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本发明涉及用于治疗药物成瘾、尼古丁成瘾和/或肥胖症的化合物、组合物和方法。这些化合物是N-芳基二氮杂螺环化合物、N-杂芳基二氮杂螺环化合物的桥接类似物或这些化合物的前药或代谢物。芳基可以是五元或六元杂环环（杂芳基）。这些化合物能够有效地抑制多巴胺的产生和/或分泌，从而有效地抑制与尼古丁和/或非法药物摄入相关的生理“奖励”过程。这些化合物和组合物可以以有效剂量给予，以抑制多巴胺的释放，而不会导致明显的不良副作用（例如，显著增加血压和心率、对胃肠道产生显著负面影响以及对骨骼肌产生显著影响等副作用）。
• N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
  申请人：Bhatti S Balwinder

  公开号：US20060217406A1

  公开（公告）日：2006-09-28

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本发明揭示了化合物、包括该化合物的制药组合物以及其制备和使用方法。该化合物为N-芳基二氮杂环螺环化合物、N-杂芳基二氮杂环螺环化合物的桥接类似物，或这些化合物的前药或代谢物。其中，芳基可以是五元或六元杂环环（杂芳基）。该化合物和组合物可用于治疗和/或预防各种疾病或障碍，特别是那些以尼古丁胆碱能神经递质功能障碍为特征的疾病，包括涉及神经递质释放的神经调节障碍，如多巴胺释放。中枢神经系统障碍，其特征是正常神经递质释放的改变，是可治疗和/或预防的另一个例子。该化合物和组合物还可用于缓解疼痛。该化合物可以：（i）改变患者大脑的尼古丁胆碱能受体数量，（ii）表现出神经保护作用，以及（iii）在有效剂量下，不会产生明显的不良副作用（例如，明显增加血压和心率、对胃肠道产生明显负面影响以及对骨骼肌产生明显影响等副作用）。
• N-Aryl Diazaspirocyclic Compounds and Methods of Preparation and Use Thereof
  申请人：Bhatti Balwinder S.

  公开号：US20080214591A1

  公开（公告）日：2008-09-04

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本文揭示了化合物、包含这些化合物的药物组合物以及其制备和使用方法。这些化合物是N-芳基二氮杂螺环化合物、N-杂芳基二氮杂螺环化合物的桥接类似物，或这些化合物的前药或代谢物。芳基基团可以是五元或六元杂环环（杂芳基）。这些化合物和组合物可用于治疗和/或预防各种疾病或障碍，特别是那些以尼古丁胆碱能神经递质功能障碍为特征的障碍，包括涉及神经递质释放的神经调节障碍，如多巴胺释放。中枢神经系统障碍是另一个可以治疗和/或预防的障碍的例子，其特征是正常神经递质释放的改变。这些化合物和组合物还可用于缓解疼痛。这些化合物可以：（i）改变患者大脑中尼古丁胆碱能受体的数量，（ii）表现出神经保护作用，（iii）在有效剂量下，不会产生明显的不良副作用（例如，明显增加血压和心率、对胃肠道产生明显的负面影响以及对骨骼肌产生明显的影响）。
• N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
  申请人：Bhatti Balwinder S.

  公开号：US20110105548A1

  公开（公告）日：2011-05-05

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本文介绍了N-芳基二氮杂螺环化合物、N-杂芳基二氮杂螺环化合物的桥接类似物以及这些化合物的前药或代谢物。芳基可以是五元或六元杂环环（杂芳基）。这些化合物和组合物可以用于治疗和/或预防各种条件或疾病，特别是那些以尼古丁乙酰胆碱神经递质功能障碍为特征的疾病，包括涉及神经递质释放的神经调节疾病，如多巴胺释放。中枢神经系统疾病是另一种可以治疗和/或预防的疾病，其特征是正常神经递质释放的改变。这些化合物和组合物也可以用于缓解疼痛。这些化合物可以：（i）改变患者大脑中尼古丁乙酰胆碱受体的数量，（ii）表现出神经保护效果，以及（iii）在有效剂量下，不会产生明显的不良副作用（例如，明显增加血压和心率、对胃肠道产生明显负面影响和对骨骼肌产生明显影响等副作用）。